Categories
Blood Cancer

Are we moving away from transplantation for the treatment of myeloma? [Video]

Fredrik Hellem Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, shares some insights into the future treatment landscape of multiple myeloma, drawing focus on the role of transplantation and whether treatment will move away from this approach. Dr Schjesvold highlights the DETERMINATION trial (NCT01208662) and also mentions upcoming trials investigating this, as well as the role of bispecifics in the future of myeloma therapy. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

Antibodies in multiple myeloma and their impact on treatment [Video]

Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, discusses recent advances in the use of antibodies for the treatment of multiple myeloma, highlighting the promise of monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), as well as bispecifics. Prof. Raje first comments on the movement of mAbs into the frontline setting and advances in quadruplet regimens. Following this, Prof. Raje highlights the DETERMINATION trial (NCT01208662), and further discusses the use of ADCs, such as belantamab mafodotin, as a single agent and in combination with other agents. To conclude, Prof. Raje discusses the promise of bispecific antibodies including teclistamab and elranatamab, and their place in the myeloma treatment landscape. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

Current and future implications of MRD in myeloma [Video]

Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses the current and future implications of measurable residual disease (MRD) in multiple myeloma. Dr Costa first highlights the importance of MRD as a powerful prognostic tool, and further discusses how it can be used to identify patients at high risk of relapse. Following this, Dr Costa discusses some ongoing and future clinical trials incorporating MRD, including the AURIGA trial (NCT03901963), the MIDAS trial (NCT04934475), and the upcoming MASTER-2 trial (NCT05231629). This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

Categories
Blood Cancer

Managing and treating renal impairment in multiple myeloma [Video]

In this video, Joan Bladé, MD, PhD, University of Barcelona, Barcelona, Spain, discusses the management and treatment of renal impairment in patients with multiple myeloma. Prof. Bladé first highlights the poorer outcomes associated with patients who present with severe renal impairment, and then discusses potential treatment combinations, including bortezomib plus dexamethasone and a third agent. Following this, Prof. Bladé shares some insights into his presentation at COMy 2022, which focused on a long-term follow-up of patients with renal impairment and the improvements that have been made in these patients over the last 50 years. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

Categories
Blood Cancer

Recent updates on CELMoDs in multiple myeloma [Video]

Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University, Atlanta, GA, shares some recent updates on cereblon E3 ligase modulators (CELMoDs) for multiple myeloma and how these novel agents are transforming the treatment landscape. Prof. Lonial first reports on some data on the use of iberdomide plus dexamethasone in patients with triple-class refractory disease. Following this, Prof. Lonial discusses the encouraging activity observed in various CELMoDs and compares this to the use of immunomodulatory imide drugs (IMiDs). To conclude, Prof. Lonial discusses the activity and safety profile of CC-92480 and the impact that CELMoDs will have on the myeloma treatment landscape. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

Categories
Blood Cancer

The future of myeloma treatment and the possibility of cure [Video]

In this video, Kenneth Anderson, MD, Dana-Farber Cancer Institute, Boston, MA, gives an overview of the future treatment of myeloma and his presentation at COMy 2022. Dr Anderson highlights his presentation which covered a variety of topics, including novel technologies used to monitor myeloma, the application of therapeutic agents, advances in immunotherapy, and novel targets. Dr Anderson then goes on to discuss precision medicine and the role of novel immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapy, antibodies, bispecific T-cell engagers (BiTEs), and the importance of achieving measurable residual disease (MRD) negativity. To conclude, Dr Anderson addresses the possibility of achieving cure in myeloma by 2030. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

Categories
Blood Cancer

Recent advances in newly diagnosed multiple myeloma and the importance of patient perspectives [Video]

Kwee Yong, PhD, FRCP, FRCPath, University College London, London, UK, discusses recent advances in the treatment of myeloma, as well as the importance of drawing focus on elderly, more frail patients. First, Prof. Yong discusses the standard of care (SOC) for patients who are transplant ineligible and further highlights the importance of using the best available tools to assess frailty. Following this, Prof. Yong shares some insights into the FiTNEss (Myeloma XIV) study (NCT03720041), and the promising future for newly diagnosed multiple myeloma. To conclude, Prof. Yong emphasizes the importance of getting a patient’s perspective during treatment, as this factor plays a major role in a patient’s overall experience. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

Categories
Blood Cancer

The evolving treatment landscape in multiple myeloma & ongoing research [Video]

Guy Pratt, MD, FRCP, FRCPath, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, discusses key advances in the management of multiple myeloma. In recent years, the introduction of anti-BCMA monoclonal antibodies and chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment landscape of multiple myeloma. Prof. Pratt also mentions the approval of the quadruplet combination of daratumumab, bortezomib, thalidomide and dexamethasone (D-VTd) in the UK. Moving forward, Prof. Pratt highlights various areas of ongoing research in multiple myeloma, including treatment sequencing, risk-adapted therapy in young patients, dose adjustments and frailty assessment in elderly patients, which is currently evaluated in the FiTNEss trial (NCT03720041), and the potential role of measurable residual disease (MRD) as a clinical endpoint, which is currently being assessed in the RADAR trial (ISRCTN46841867; UK-MRA Myeloma XV).

Categories
Blood Cancer

Management of newly diagnosed patients with multiple myeloma not eligible for transplantation [Video]

Maximilian Merz, MD, Leipzig University, Leipzig, Germany, Roswell Park Comprehensive Center Institute, Buffalo, NY, comments on the management of patients with multiple myeloma not eligible for transplant, where a paradigm shift has been observed after the introduction of CD38 antibodies to upfront therapy, with higher rates of progression-free survival (PFS) and overall survival (OS) and long-lasting remissions. Data from the ALCYONE (NCT02195479) and MAIA (NCT02252172) trials led to the approval of several combinations of daratumumab, with a notable outcome improvement in elderly and frail patients. Dr Merz considers that the standard of care should point to antibody plus lenalidomide-dexamethasone (Rd) or bortezomib-melphalan-prednisone (VMP), but more data on quadruplet therapy for ineligible patients is needed. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.

Categories
Blood Cancer

Current approaches for the management of patients with high-risk multiple myeloma [Video]

There are currently multiple strategies to treat patients with high-risk multiple myeloma. In this video, Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, outlines how patients with high-risk disease are treated at Emory University. Patients first receive carfilzomib-lenalidomide-dexamethasone (KRd) induction therapy before undergoing autologous stem cell transplantation (autoSCT) followed by KRd consolidation and maintenance for three years. This strategy is based on the results of the FORTE study (NCT02203643) which showed that this patient population benefited from this regimen and achieved sustained measurable residual disease (MRD) negativity. There are currently discussions about incorporating daratumumab in this regimen, but clinical trials have not yet shown a significant benefit for this high-risk population. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.

Categories
Blood Cancer

Molecular underpinnings of MRD negativity in newly diagnosed myeloma patients treated with D-KRd [Video]

In this video, Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, discusses some interesting results from a study which investigated factors predicting sustained minimal residual disease (MRD) negativity in patients with newly diagnosed multiple myeloma (MM). Dr Landgren first highlights some results from the MANHATTAN trial (NCT03290950), which investigated the safety and efficacy of daratumumab in combination with carfilzomib, lenalidomide and dexamethasone (D-KRd) in the treatment of newly diagnosed MM. Based on the promising results of this trial, Dr Landgren then discusses the aim of the current study to better understand the mechanisms behind MRD negativity. Using both single-cell sequencing and whole-genome sequencing, Dr Landgren explains the main findings, which show that there is a complex interplay of the immune microenvironment and tumor genomics associated with sustained MRD negativity. To conclude, Dr Landgren mentions the importance of this study, as it provides important insights into the role of the immune microenvironment in disease and may help to improve future studies in myeloma. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.

Categories
Blood Cancer

FDA Approves Cell Based Multiple Myeloma Therapy Discovered in China l ION International [Video]

FDA Approves Cell Based Multiple Myeloma Therapy Discovered in China l ION International✅ IF YOU LIKE AND LOVE THIS VIDEO PLEASE SUBSCRIBE OUR CHANNEL.🌐subscribe here :———————————–https://www.youtube.com/IONInternational✅ fb page: https://www.facebook.com/ioninternational✅ website: https://ioninternational.blogspot.comFDA Approves Cell-Based Multiple Myeloma Therapy Discovered in ChinaJohnson & Johnson acquired rights to the new drug and conducted studies in the U.S. confirming it worked safelyU.S. drug regulators approved a new customized, cell-based treatment for blood cancer from Johnson & Johnson that is the first such therapy in the U.S. to be developed initially in China.The Food and Drug Administration on Monday cleared the therapy, named Carvykti, for the treatment of multiple myeloma in adult patients whose disease has worsened despite prior treatments with other drugs.The approval suggests a possible path forward for Western drugmakers seeking to bring China-developed drugs to the U.S. amid concerns about the quality of the drugs’ development: conducting separate, confirmatory studies in Americans.In one of J&J’s U.S. studies, about 98% of the 97 multiple-myeloma patients treated with Carvykti had a significant reduction in the proteins that signal the presence of myeloma, and 83% had a complete remission, indicating no detectable cancer cells, at a median of 22 months after treatment.Joseph Mikhael, chief medical officer of the International Myeloma Foundation, said the effectiveness demonstrated in the study was “really unprecedented. That’s why there’s so much excitement around it.”Multiple myeloma is a cancer affecting plasma cells, and although other treatments have extended patients’ survival in recent years, it is estimated to cause more than 12,400 deaths each year in the U.S., according to the American Cancer Society.J&J’s Carvykti belongs to a class of therapies known as CAR-T, short for chimeric antigen receptor T cell. CAR-T is a complex treatment that starts with extracting a patient’s own T-cells, the infection-fighting white blood cells that are part of the immune system.U.S. drug regulators approved a new customized, cell-based treatment for blood cancer from Johnson & Johnson that is the first such therapy in the U.S. to be developed initially in China.The Food and Drug Administration on Monday cleared the therapy, named Carvykti, for the treatment of multiple myeloma in adult patients whose disease has worsened despite prior treatments with other drugs.The approval suggests a possible path forward for Western drugmakers seeking to bring China-developed drugs to the U.S. amid concerns about the quality of the drugs’ development: conducting separate, confirmatory studies in Americans.In one of J&J’s U.S. studies, about 98% of the 97 multiple-myeloma patients treated with Carvykti had a significant reduction in the proteins that signal the presence of myeloma, and 83% had a complete remission, indicating no detectable cancer cells, at a median of 22 months after treatment.Joseph Mikhael, chief medical officer of the International Myeloma Foundation, said the effectiveness demonstrated in the study was “really unprecedented. That’s why there’s so much excitement around it.”#FDA #CellBased #MultipleMyeloma #Therapy #DiscoveredChina